# EDGAR Filing Document

**Accession Number:** 0001810747
**File Stem:** 0000940400-26-021308
**Filing Date:** 2026-5
**Character Count:** 27152
**Document Hash:** 7776b07c05354cc2d1931c067d0f06fc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000940400-26-021308.hdr.sgml**: 20260527

**ACCESSION NUMBER**: 0000940400-26-021308

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260527

**DATE AS OF CHANGE**: 20260527

**PERIOD START**: 20260630

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Simplify Exchange Traded Funds
- **CENTRAL INDEX KEY:** 0001810747

**ORGANIZATION NAME:**
- **EIN:** 851887571
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-23570
- **FILM NUMBER:** 261023896

**BUSINESS ADDRESS:**
- **STREET 1:** 222 BROADWAY
- **STREET 2:** 22ND FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10038
- **BUSINESS PHONE:** 646-741-2438

**MAIL ADDRESS:**
- **STREET 1:** 222 BROADWAY
- **STREET 2:** 22ND FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10038

## Series and Classes Contracts Data

### Simplify Propel Opportunities ETF (Series ID: S000078061)

| Class ID   | Class Name                        | Ticker Symbol   |
|:---|:---|:---|
| C000238807 | Simplify Propel Opportunities ETF | SURI            |

## Nport-Ex

#### Simplify

#### Propel

#### Opportunities

#### ETF

#### Schedule

#### of

#### Investments
March

31,

2026

(Unaudited)

#### Principal

#### Value

#### U.S.

#### Treasury

#### Bills

#### –

#### 92.9%
U.S.

Treasury

Bill,

6/25/2026

(a)(b) (Cost

$64,449,747)

.......................................................

$

65,000,000

$

64,450,057

#### Shares

#### Common

#### Stocks

#### –

#### 52.7%

#### Health

#### Care

#### –

#### 52.7%
4d

Molecular

Therapeutics,

Inc.\*

..............................................

70,430

655,703

Abeona

Therapeutics,

Inc.\*

...................................................

500,342

2,241,532

Achieve

Life

Sciences,

Inc.\*

..................................................

1,184,512

3,482,465

Aquestive

Therapeutics,

Inc.\*

.................................................

234,279

972,258

Artiva

Biotherapeutics,

Inc.\*

..................................................

23,230

149,601

Celldex

Therapeutics,

Inc.\*

...................................................

68,994

2,188,490

Chinook

Therapeutics,

Inc.\*(c)

................................................

25,000

2,500

Coherus

Oncology,

Inc.\*

.....................................................

253,140

427,807

Compass

Pathways

PLC,

ADR\*

...............................................

159,052

879,558

Connect

Biopharma

Holdings

Ltd.\*

.............................................

51,475

134,864

Corcept

Therapeutics,

Inc.\*

...................................................

37,763

1,522,227

Corvus

Pharmaceuticals,

Inc.\*

................................................

20,242

296,140

Delcath

Systems,

Inc.\*

......................................................

261,126

2,423,249

Eiger

BioPharmaceuticals,

Inc.\*(c)

.............................................

90,000

900

EyePoint,

Inc.\*

.............................................................

53,526

689,950

Immunic,

Inc.\*

.............................................................

438,932

487,215

Inventiva

Saca,

ADR\*

.......................................................

227,923

1,264,973

Kalaris

Therapeutics,

Inc.\*

...................................................

87,426

504,448

Kyverna

Therapeutics,

Inc.\*

..................................................

173,106

1,493,905

Leonabio,

Inc.\*

............................................................

149,279

1,534,588

Milestone

Pharmaceuticals,

Inc.\*

..............................................

1,506,405

1,792,622

Novo

Nordisk

A/S\*(c)

.......................................................

145,609

426,634

Ocular

Therapeutix,

Inc.\*

....................................................

90,000

762,300

Oculis

Holding

AG\*

.........................................................

66,667

1,772,676

Orchestra

BioMed

Holdings,

Inc.\*

..............................................

219,387

932,395

Ovid

Therapeutics,

Inc.\*

.....................................................

130,813

290,405

Palisade

Bio,

Inc.\*

..........................................................

350,000

612,500

Phathom

Pharmaceuticals,

Inc.\*

...............................................

262,386

2,915,108

Sab

Biotherapeutics,

Inc.\*

....................................................

187,230

717,091

Trevi

Therapeutics,

Inc.\*

.....................................................

65,412

780,365

Upstream

Bio,

Inc.\*

.........................................................

77,793

700,137

Viridian

Therapeutics,

Inc.\*

...................................................

56,231

1,099,878

Vor

Biopharma,

Inc.\*

........................................................

53,510

954,618

WTS

-

Achieve

Life

Science,

Inc.\*(c)

...........................................

966,667

Zealand

Pharma

A/S\*

.......................................................

12,330

568,783

Zevra

Therapeutics,

Inc.\*

....................................................

96,246

897,013

Total

Common

Stocks

(Cost

$51,346,354)

...........................................

36,574,899

#### Limited

#### Partnership

#### –

#### 44.6%

#### Energy

#### –

#### 44.6%
Plains

GP

Holdings

LP,

Class

A

(Cost

$4,616,206)

........................................................

1,272,360

30,892,901

#### Simplify

#### Propel

#### Opportunities

#### ETF

#### Schedule

#### of

#### Investments
(Continued)

March

31,

2026

(Unaudited)

#### Principal

#### Value

#### Corporate

#### Bonds

#### –

#### 1.2%

#### Communications

#### –

#### 1.2%
Telesat

Canada

/

Telesat

LLC,

5.63%,

12/6/2026,

144A(d)

(Cost

$894,285)

..........................................................

$

1,000,000

$

800,000

#### Shares

#### Warrants

#### –

#### 0.0%†

#### Health

#### Care

#### –

#### 0.0%†
Jasper

Therapeutics,

Inc.,

Expires

12/31/49\*(c)

...................................

609,053

Milestone

Pharmaeuticals,

Inc.,

Series

A,

Expires

7/14/26\*(c)

.......................

1,842,974

Milestone

Pharmaeuticals,

Inc.,

Series

B,

Expires

7/14/30\*(c)

.......................

1,842,974

Quoin

Pharmaceuticals

Ltd.,

ADR,

Series

H,

Expires

10/10/30\*(c)

....................

34,895

Quoin

Pharmaceuticals

Ltd.,

ADR,

Series

I,

Expires

10/10/30\*(c)

.....................

34,895

Quoin

Pharmaceuticals

Ltd.,

ADR,

Series

J,

Expires

10/10/30\*(c)

....................

34,895

Quoin

Pharmaceuticals

Ltd.,

ADR,

Series

K,

Expires

10/10/30\*(c)

....................

34,895

Tenaya

Therapeutics,

Inc,

Expires

12/12/30\*(c)

...................................

560,000

Total

Warrants

(Cost

$–)

.........................................................

Total

Investments

–

191.4%

(Cost

$121,306,592)

............................................................

$

132,717,862

Liabilities

in

Excess

of

Other

Assets

–

(91.4)%

.........................................

(63,367,583)

#### Net

#### Assets

#### –

#### 100.0%

#### .............................................................

#### $

#### 69,350,279
\*

Non

Income

Producing

†

Less

than

0.05%

(a) Represents

a

zero

coupon

bond.

Rate

shown

reflects

the

effective

yield.

(b) Security,

or

a

portion

thereof,

in

the

amount

of

$64,441,194

has

been

pledged

as

collateral

for

reverse

repurchase

agreements

as

of

March

31,

2026. (c) Investment

was

valued

using

significant

un

observable

inputs.

(d) Security

was

purchased

(sold)

pursuant

to

Rule

144A

under

the

Securities

Act

of

1933

and

may

not

be

resold

(repurchased)

subject

to

that

rule

except

to

qualified

institutional

buyers.

Unless

otherwise

noted,

Rule

144A

securities

are

deemed

to

be

liquid.

Total

fair

value

of

Rule

144A

securities

amounts

to

$800,000,

which

represents

1.2%

of

net

assets

as

of

March

31,

2026. #### Abbreviations:
ADR

:

American

Depositary

Receipt

#### At

#### March

#### 31,

#### 2026,

#### open

#### reverse

#### repurchase

#### agreements

#### were

#### as

#### follows:

#### Counterparty

#### Interest

#### Rate

#### Trade

#### Date

#### Maturity

#### Date

#### Face

#### Amount

#### Payable

#### for

#### Reverse

#### Repurchase

#### Agreements
Morgan

Stanley

Capital

Services

LLC

3.90%

3/31/2026

4/2/2026

$

63,152,370

$

63,152,370

$

63,152,370

$

63,152,370

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** Simplify Exchange Traded Funds

- **b. Investment Company Act file number:** 811-23570

- **c. CIK number of Registrant:** 0001810747

- **d. LEI of Registrant:** 549300LDDEMEUCZQEO55

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 10845 Griffith Peak Drive

  - **City:** Las Vegas

  - **State:** NV

  - **Foreign country:** US

  - **Zip / Postal Code:** 89135

  - **Telephone number:** (702) 389-9705

**Item A.2. Information about the Series.**

- **a. Name of Series:** Simplify Propel Opportunities ETF

- **b. EDGAR series identifier (if any):** S000078061

- **c. LEI of Series:** 549300DJ9GVPZFC9VR09

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2026-06-30

- **b. Date as of which information is reported:** 2026-03-31

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $132662073.60

**Total Liabilities:** $63311780.40

**Net Assets:** $69350293.20

**Currency Risk Metrics (dv01):**

- 

**Credit Spread Risk - Investment Grade (dv01):**

- **3-Month:** 0.00000000 | **1-Year:** 0.00000000 | **5-Year:** 0.00000000 | **10-Year:** 0.00000000 | **30-Year:** 0.00000000

**Credit Spread Risk - Non-Investment Grade (dv01):**

- **3-Month:** 23.58400000 | **1-Year:** 30.01600000 | **5-Year:** 0.00000000 | **10-Year:** 0.00000000 | **30-Year:** 0.00000000

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000238807 | -1.96%               | 4.83%                | -5.59%               |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $-439512.32              | $-1441814.18                               |
| Month 2  | $1726931.70              | $1980178.93                                |
| Month 3  | $-118311.11              | $-3994542.56                               |

**Designated Index Information**

- **Index Name:** Self Reference

- **Index Identifier:** N/A

### Schedule of Portfolio Investments

| Name                           | Title                                  | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Compass Pathways plc           | Compass Pathways plc SPONSORED ADS     | CUSIP: 20451W101<br>LEI: 213800N7CUZIC6QSTZ31 | Long             | EC               | CORP              | GB        |    159052 | NS      | $879557.56    | 1.27%             |  |  |  | No            |                  1 | On Loan: No      |
| MILESTONE PHARMACE WTS         | MILESTONE PHARMACE WTS                 | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   1842974 | NS      | $1.84         | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| WTS - TENAYA THERAPEUTICS      | WTS - TENAYA THERAPEUTICS              | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    560000 | NS      | $0.56         | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| MORGAN STANLEY & CO. LLC       | Morgan Stanley                         | CUSIP: 000000000<br>LEI: 9R7GPTSO7KV3UQJZQ078 | Short            | RA               | CORP              | US        | -63152370 | PA      | $-63152370.00 | -91.06%           |  |  |  | No            |                  2 | On Loan: No      |
| Ocular Therapeutix Inc         | Ocular Therapeutix Inc COM             | CUSIP: 67576A100<br>LEI: 529900ABAWFXOHSIHG03 | Long             | EC               | CORP              | US        |     90000 | NS      | $762300.00    | 1.10%             |  |  |  | No            |                  1 | On Loan: No      |
| Immunic Inc.                   | Immunic Inc. COM                       | CUSIP: 4525EP101<br>LEI: 549300R5T12FW5MEQB20 | Long             | EC               | CORP              | US        |    438932 | NS      | $487214.52    | 0.70%             |  |  |  | No            |                  1 | On Loan: No      |
| QUOIN PHARMACEUTIC WTS         | QUOIN PHARMACEUTIC WTS                 | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     34895 | NS      | $0.03         | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| Achieve Life Science Inc       | Achieve Life Science Inc COM           | CUSIP: 004468500<br>LEI: 549300V82ZKZDTAU0A46 | Long             | EC               | CORP              | US        |   1184512 | NS      | $3482465.28   | 5.02%             |  |  |  | No            |                  1 | On Loan: No      |
| Phathom Pharmaceuticals Inc    | Phathom Pharmaceuticals Inc COM        | CUSIP: 71722W107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    262386 | NS      | $2915108.46   | 4.20%             |  |  |  | No            |                  1 | On Loan: No      |
| Akero Therapeutics Inc         | Akero Therapeutics Inc                 | CUSIP: 009CVR044<br>LEI: 549300SI3KG74LBE2955 | Long             | EC               | CORP              | US        |    145609 | NS      | $426634.37    | 0.62%             |  |  |  | No            |                  3 | On Loan: No      |
| Celldex Therapeutics Inc.      | Celldex Therapeutics Inc. COM NEW      | CUSIP: 15117B202<br>LEI: 529900F018DMYWH38923 | Long             | EC               | CORP              | US        |     68994 | NS      | $2188489.68   | 3.16%             |  |  |  | No            |                  1 | On Loan: No      |
| Coherus Oncology Inc.          | Coherus Oncology Inc. COM              | CUSIP: 19249H103<br>LEI: 5493007IL8W5MV932D26 | Long             | EC               | CORP              | US        |    253140 | NS      | $427806.60    | 0.62%             |  |  |  | No            |                  1 | On Loan: No      |
| Ovid Therapeutics Inc          | Ovid Therapeutics Inc COM              | CUSIP: 690469101<br>LEI: 549300H36NUI4L6U8F17 | Long             | EC               | CORP              | US        |    130813 | NS      | $290404.86    | 0.42%             |  |  |  | No            |                  1 | On Loan: No      |
| QUOIN PHARMACEUTIC WTS         | QUOIN PHARMACEUTIC WTS                 | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     34895 | NS      | $0.03         | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| Eyepoint Inc.                  | Eyepoint Inc. COM NEW                  | CUSIP: 30233G209<br>LEI: 549300QE1RU34T50MR69 | Long             | EC               | CORP              | US        |     53526 | NS      | $689950.14    | 0.99%             |  |  |  | No            |                  1 | On Loan: No      |
| LeonaBio Inc.                  | LeonaBio Inc. COM                      | CUSIP: 04746L203<br>LEI: 529900CSS4S4X8VY5C81 | Long             | EC               | CORP              | US        |    149279 | NS      | $1534588.12   | 2.21%             |  |  |  | No            |                  1 | On Loan: No      |
| Achieve Life Science Inc       | Achieve Life Science Inc WT EXP 063030 | CUSIP: 004468187<br>LEI: 549300V82ZKZDTAU0A46 | Long             | EC               | CORP              | US        |    966667 | NS      | $0.97         | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| Milestone Pharmaceuticals Inc  | Milestone Pharmaceuticals Inc COM      | CUSIP: 59935V107<br>LEI: N/A                  | Long             | EC               | CORP              | CA        |   1506405 | NS      | $1792621.95   | 2.58%             |  |  |  | No            |                  1 | On Loan: No      |
| KALARIS THERAPEUTICS INC       | Kalaris Therapeutics Inc. COM          | CUSIP: 482929106<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     87426 | NS      | $504448.02    | 0.73%             |  |  |  | No            |                  1 | On Loan: No      |
| United States Treasury Bills   | B 0 06/25/26                           | CUSIP: 912797TE7<br>LEI: 254900HROIFWPRGM1V77 | Long             | DBT              | UST               | US        |  65000000 | PA      | $64450057.75  | 92.93%            | 2026-06-25      | None          | 0.00%                 | No            |                  1 | On Loan: No      |
| Abeona Therapeutics Inc.       | Abeona Therapeutics Inc. COM NEW       | CUSIP: 00289Y206<br>LEI: 54930002Z8PIJRCB4576 | Long             | EC               | CORP              | US        |    500342 | NS      | $2241532.16   | 3.23%             |  |  |  | No            |                  1 | On Loan: No      |
| QUOIN PHARMACEUTIC WTS         | QUOIN PHARMACEUTIC WTS                 | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     34895 | NS      | $0.03         | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| Oculis Holding AG              | Oculis Holding AG ORDINARY SHARES      | CUSIP: 000000000<br>LEI: 5067005370C2KK324336 | Long             | EC               | CORP              | CH        |     66667 | NS      | $1772675.53   | 2.56%             |  |  |  | No            |                  1 | On Loan: No      |
| MILESTONE PHARMACE WTS         | MILESTONE PHARMACE WTS                 | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   1842974 | NS      | $1.84         | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| Inventiva SA                   | Inventiva SA ADS                       | CUSIP: 46124U107<br>LEI: 969500I9Y690B3FZW590 | Long             | EC               | CORP              | FR        |    227923 | NS      | $1264972.65   | 1.82%             |  |  |  | No            |                  1 | On Loan: No      |
| ARTIVA BIOTHERAPEUTICS INC     | Artiva Biotherapeutics Inc. COM        | CUSIP: 04317A107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     23230 | NS      | $149601.20    | 0.22%             |  |  |  | No            |                  1 | On Loan: No      |
| Trevi Therapeutics Inc         | Trevi Therapeutics Inc COM             | CUSIP: 89532M101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     65412 | NS      | $780365.16    | 1.13%             |  |  |  | No            |                  1 | On Loan: No      |
| QUOIN PHARMACEUTIC WTS         | QUOIN PHARMACEUTIC WTS                 | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     34895 | NS      | $0.03         | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| VOR BIOPHARMA INC              | Vor Biopharma Inc. COM NEW             | CUSIP: 929033207<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     53510 | NS      | $954618.40    | 1.38%             |  |  |  | No            |                  1 | On Loan: No      |
| Aquestive Therapeutics Inc     | Aquestive Therapeutics Inc COM         | CUSIP: 03843E104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    234279 | NS      | $972257.85    | 1.40%             |  |  |  | No            |                  1 | On Loan: No      |
| Plains GP Holdings LP          | Plains GP Holdings LP LTD PARTNR INT A | CUSIP: 72651A207<br>LEI: 549300O56BSKRD8FAM12 | Long             | EC               | CORP              | US        |   1272360 | NS      | $30892900.80  | 44.55%            |  |  |  | No            |                  1 | On Loan: No      |
| Upstream Bio Inc               | Upstream Bio Inc COM                   | CUSIP: 91678A107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     77793 | NS      | $700137.00    | 1.01%             |  |  |  | No            |                  1 | On Loan: No      |
| Sab Biotherapeutics Inc        | Sab Biotherapeutics Inc COM NEW        | CUSIP: 78397T202<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    187230 | NS      | $717090.90    | 1.03%             |  |  |  | No            |                  1 | On Loan: No      |
| Zevra Therapeutics Inc         | Zevra Therapeutics Inc COM NEW         | CUSIP: 488445206<br>LEI: 254900CU6T74V18Y1W18 | Long             | EC               | CORP              | US        |     96246 | NS      | $897012.72    | 1.29%             |  |  |  | No            |                  1 | On Loan: No      |
| 4D Molecular Therapeutics Inc  | 4D Molecular Therapeutics Inc COM      | CUSIP: 35104E100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     70430 | NS      | $655703.30    | 0.95%             |  |  |  | No            |                  1 | On Loan: No      |
| Zealand Pharma As              | Zealand Pharma As DKK1                 | CUSIP: 000000000<br>LEI: 549300ITBB1ULBL4CZ12 | Long             | EC               | CORP              | DK        |     12330 | NS      | $568782.90    | 0.82%             |  |  |  | No            |                  1 | On Loan: No      |
| Kyverna Therapeutics Inc       | Kyverna Therapeutics Inc COM           | CUSIP: 501976104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    173106 | NS      | $1493904.78   | 2.15%             |  |  |  | No            |                  1 | On Loan: No      |
| Corcept Therapeutics Inc.      | Corcept Therapeutics Inc. COM          | CUSIP: 218352102<br>LEI: 529900EO9LUTFMZ7FF90 | Long             | EC               | CORP              | US        |     37763 | NS      | $1522226.53   | 2.19%             |  |  |  | No            |                  1 | On Loan: No      |
| Viridian Therapeutics Inc      | Viridian Therapeutics Inc COM          | CUSIP: 92790C104<br>LEI: 549300C775BNYF550E70 | Long             | EC               | CORP              | US        |     56231 | NS      | $1099878.36   | 1.59%             |  |  |  | No            |                  1 | On Loan: No      |
| Orchestra BioMed Holdings Inc  | Orchestra BioMed Holdings Inc COM      | CUSIP: 68572M106<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    219387 | NS      | $932394.75    | 1.34%             |  |  |  | No            |                  1 | On Loan: No      |
| Telesat Canada /Telesat LLC    | TELSAT 5.625 12/06/26 144A             | CUSIP: 87952VAR7<br>LEI: 5493004V5GLBY6SO5Y34 | Long             | DBT              | CORP              | CA        |   1000000 | PA      | $800000.00    | 1.15%             | 2026-12-06      | Fixed         | 5.62%                 | No            |                  2 | On Loan: No      |
| Delcath Systems Inc.           | Delcath Systems Inc. COM NEW           | CUSIP: 24661P807<br>LEI: 549300NVPLITUM6URT02 | Long             | EC               | CORP              | US        |    261126 | NS      | $2423249.28   | 3.49%             |  |  |  | No            |                  1 | On Loan: No      |
| CONNECT BIOPHARMA HOLDINGS LTD | Connect Biopharma Holdings Limited SHS | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | KY        |     53375 | NS      | $139842.50    | 0.20%             |  |  |  | No            |                  1 | On Loan: No      |
| Palisade Bio Inc               | Palisade Bio Inc COM                   | CUSIP: 696389402<br>LEI: 549300W6LIDX3I5XXT34 | Long             | EC               | CORP              | US        |    350000 | NS      | $612500.00    | 0.88%             |  |  |  | No            |                  1 | On Loan: No      |
| Chinook Therapeutics Inc       | Chinook Therapeutics Inc SHS           | CUSIP: 169CVR016<br>LEI: 549300X0O3003W5QYQ48 | Long             | EC               | CORP              | US        |     25000 | NS      | $2500.00      | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| JASPER THERAPEUTIC WTS         | JASPER THERAPEUTIC WTS                 | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    609053 | NS      | $0.61         | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| Eiger BioPharmaceuticals Inc   | Eiger BioPharmaceuticals Inc           | CUSIP: 28249U204<br>LEI: 549300GO4VMIHDKJNU46 | Long             | EC               | CORP              | US        |     90000 | NS      | $900.00       | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| Corvus Pharmaceuticals Inc     | Corvus Pharmaceuticals Inc COM         | CUSIP: 221015100<br>LEI: 549300I3AVJ8F75NCX65 | Long             | EC               | CORP              | US        |     20242 | NS      | $296140.46    | 0.43%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2026-05-27

**Name of Applicant:** Simplify Exchange Traded Funds

**Signature:** Paul Kim

**Name of Signer:** Paul Kim

**Title:** Trustee & President